IMMUNITYBIO, INC. Intangible Assets, Net (Including Goodwill)
IMMUNITYBIO, INC. (IBRX) had Intangible Assets, Net (Including Goodwill) of $11.84 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Goodwill and Other
us-gaap:IntangibleAssetsNetIncludingGoodwill · last filed 2026-08-04
- 2026-06-30: Intangible Assets, Net (Including Goodwill) $11.84M.
- 2026-03-31: Intangible Assets, Net (Including Goodwill) $12.88M.
- 2025-12-31: Intangible Assets, Net (Including Goodwill) $13.95M.
- 2025-09-30: Intangible Assets, Net (Including Goodwill) $14.47M.
| Period end | Intangible Assets, Net (Including Goodwill) |
|---|---|
| 2026-06-30 | $11.84M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $12.88M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $13.95M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $14.47M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $14.98M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $15.44M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $15.93M 10-K · filed 2026-02-23 |
| 2024-09-30 | $16.48M 10-Q · filed 2024-11-12 |
| 2023-12-31 | $17.09M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |